



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
May 5, 2020

Therapeutic Class	Drug Name	DURB Recommendation
Acne and Rosacea Agents, Topical		
	<i>Aklief (Topical) Cream</i>	NP/PA
Contraceptives, Other		
	<i>Anovera (Vaginal) System</i>	NP/PA
Macular Degeneration Agents		
	<i>Beovu (Intravitreal) Injection</i>	P/PA (for coverage on the PADL)
Antiparkinson's Agents		
	<i>Nourianz (Oral) Tablet</i>	NP/PA
Biologic Immunomodulators		
	<i>Rinvoq (Oral) Tablet</i>	NP/PA
Multiple Sclerosis Agents		
	<i>Vumerity (Oral) Capsule</i>	NP/PA
Pleuromutilins		
	<i>Xenleta (Oral) Tablet</i>	NP/PA
	<i>Xenleta (Intravenous) Injection</i>	NP/PA
Antimigraine Agents, Other		
	<i>Ajovy (Subcutaneous) Injection</i>	P/PA
	<i>Emgality (Subcutaneous) Injection</i>	P/PA

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List